Change over period: —
NSE · VIYASH
VIYASH
-19.9% from the 52-week high · +31.0% above the low
SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Bangalore, Karnataka and currently employs 1,958 full-time employees. The company went IPO on 2016-03-10. The firm operates in the domains of animal health, in which it provides active pharmaceutical ingredient (APIs) and finished dosage formulations, and analytical services. The firm through its subsidiary, Alivira Animal Health Limited, offers APIs and formulations. Alivira Animal Health Limited has manufacturing facilities in five countries, including India. The Company’s subsidiary, Sequent Research Limited, is a contract research organization, which is engaged in analytical and biological analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. Sequent Research Limited provides complete analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopeial monographs, customer-developed methods or in-house method development.
The short version. VIYASH reported revenue of ₹988 crore for Sep 2026, up 133.0% from a year earlier. Net profit was ₹76 crore (up 406.7% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 49.24% in Sep 2026, down 3.37 points over 8 quarters.
1 · The price
How has the stock traded?
VIYASH trades 19.9% below its 52-week high and 31.0% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹988 cr.
Sep 2026 net profit of ₹76 cr.
4.2 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 988 | 946 | 920 | 858 | 424 | 441 | 402 | 391 |
| Net profit | 76 | 66 | 52 | 38 | 15 | 14 | 9 | 3 |
| Net margin % | 7.7 | 7.0 | 5.7 | 4.5 | 3.5 | 3.2 | 2.3 | 0.9 |
| EPS (₹) | 1.72 | 1.51 | 1.19 | 0.88 | 0.59 | 0.57 | 0.37 | 0.14 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3420 | 1551 | 1370 | 1421 | 1413 | 1362 | 1179 | 1039 |
| Net profit | 177 | 22 | -36 | -121 | 41 | 95 | 70 | 49 |
| Net margin % | 5.2 | 1.4 | -2.6 | -8.5 | 2.9 | 7.0 | 5.9 | 4.7 |
| EPS (₹) | 4.06 | 0.87 | -1.44 | -4.86 | 1.66 | 3.84 | 2.81 | 1.97 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.1% in Mar 2026; debt to equity is 0.15.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 6.1 | 3.1 | -5.5 | -17.3 |
| Return on capital % | 11.4 | 9.6 | -0.7 | -10.2 |
| EBITDA margin % | 18.8 | 10.9 | 4.0 | -3.2 |
| Net margin % | 5.1 | 1.4 | -2.6 | -8.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 34.4% | 20.4% |
| Profit CAGR | — | 13.2% |
4 · The owners
Who holds it, and are they adding?
Down 3.37 pts over 8 quarters.
Down 3.5 pts over 8 quarters.
Down 3.72 pts over 8 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 52.61 | 52.61 | 52.61 | 52.33 | 61.41 | 61.31 | 61.31 | 49.24 | -3.37 |
| FII | 6.1 | 6.05 | 6.15 | 5.91 | 3.16 | 2.94 | 4.5 | 2.6 | -3.5 |
| DII | 12.02 | 12.82 | 12.99 | 12.91 | 7.36 | 7.99 | 3.75 | 8.3 | -3.72 |
| Public | 29.11 | 28.36 | 28.1 | 28.69 | 27.97 | 27.67 | 30.34 | 39.76 | +10.65 |
Mutual fund holdings · Oct 2026
28 schemes hold this stock
24 the month before.
- Kotak Special Opportunities Fund2.14% of NAV
- Kotak Manufacture In India Fund1.53% of NAV
- Kotak Healthcare Fund1.52% of NAV
- UTI - Healthcare Fund1.36% of NAV
- Kotak Consumption Fund1.35% of NAV
- Kotak ELSS Tax Saver Fund1.29% of NAV
- Kotak MNC Fund1.28% of NAV
- EDELWEISS SMALL CAP FUND1.18% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for VIYASH are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about VIYASH
What is the VIYASH share price?
VIYASH (VIYASH) last closed at ₹235.84, up 0.1% on the day. Its 52-week range is ₹179.89 to ₹294.15.
What is the market cap of VIYASH?
VIYASH has a market capitalisation of about ₹10,400 crore. Its price-to-earnings ratio is 45.9.
How are VIYASH's latest results?
VIYASH reported revenue of ₹988 crore for Sep 2026, up 133.0% from a year earlier. Net profit was ₹76 crore (up 406.7% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 49.24% in Sep 2026, down 3.37 points over 8 quarters.
Who owns VIYASH?
As of Sep 2026, shareholding was: Promoter 49.24%, FII 2.6%, DII 8.3%, Public 39.76%.
How many mutual funds hold VIYASH?
28 mutual fund schemes held VIYASH in October 2026. That compares with 24 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.